Oklahoma Medicaid Expands Access to Opioid Use Disorder Medication

September 18, 2026 - 10:07

Oklahoma Medicaid recipients will have an easier time getting a long-acting medication used to treat opioid use disorder. The state Health Care Authority has removed prior authorization requirements for the injectable form of buprenorphine, a change meant to get treatment to patients faster.

Under the old rules, doctors had to submit paperwork and wait for approval before a patient could start the medication. That process could take days, and those delays often meant people left treatment or relapsed before the drug ever reached them. The new policy lets providers prescribe the injection without that step.

Buprenorphine works by reducing cravings and withdrawal symptoms. The long-acting version is given as a shot that lasts about a month, which helps patients who struggle to take a daily pill. State officials say the change is part of a broader push to lower overdose deaths and make addiction treatment easier to obtain.

Providers across Oklahoma have welcomed the move. They point out that quick access matters most in the first hours after someone asks for help. Removing the approval hurdle means a patient can receive the medication during that same visit.

Oklahoma continues to rank among the states hit hardest by the opioid crisis. Health officials say expanding medication options is one of the most effective tools available, and they expect the simpler rules to increase the number of people who stay in treatment.